Chemogenomics in Drug Discovery: A Medicinal Chemistry Perspective / Edition 1

Hardcover (Print)
Buy New
Buy New from BN.com
$228.25
Used and New from Other Sellers
Used and New from Other Sellers
from $43.52
Usually ships in 1-2 business days
(Save 84%)
Other sellers (Hardcover)
  • All (6) from $43.52   
  • New (4) from $139.94   
  • Used (2) from $43.52   

Overview

Chemogenomics brings together the most powerful concepts in modern chemistry and biology, linking combinatorial chemistry with genomics and proteomics.
This first reference devoted to the topic covers all stages of the early drug discovery process, from target selection to compound library and lead design.
With the combined expertise of 20 research groups from academia and leading pharmaceutical companies, this is a must-have for every drug developer and medicinal chemist applying the powerful methods of chemogenomics to speed up the drug discovery process.
Read More Show Less

Editorial Reviews

From the Publisher
"In summary, this book provides up-to-date insights into the world of chemogenomics. Most chapters are of excellent quality, providing numerous and diverse contributions from industrial practice. "Chemogenomics in Drug Discovery" offers a practical definition of chemogenomics in order to foster a clear understanding of this genome-wide drug-discovery approach. The book is valuable for graduate students anf for academic and industrial researchers who want to learn about modern drug-discovery approaches."
CHEMBIOCHEM - A European Journal of Chemical Biology

"The contributions in >Chemogenomics in Drug Discovery< are of very high quality and are clearly presented ... All chapters have a high scientific value, and collectively they contribute a great deal to the understanding of how chemogenomics and scaled-up medicinal chemistry can support the early stages of drug discovery. Therefore, this work is highly relevant for everyone with an intereste in modern drug development, and especially for readers in the pharmaceutical industry."
Ulf B?rjesson, Institute of Pharmaceutical Chemistry, University of Marburg, Angewandte Chemie, IE, 3rd May Issue 2005-44/19+ Angewandte Chemie, 3. Maiheft 2005-117/19

"... readers hoping to learn about specific aspects will be rewarded with superb writing, good discussions, and excellent examples from current literature."
Steven M. Firestine, Division of Pharmaceutical Sciences, Mylan School of Pharmacy, Duquesne University, Pittsburgh, Journal of Medicinal Chemistry,
Vol. 48, No. 11/2005

"This hallmark text marks a breakthrough in the field...vital to the researcher."
Electric Review, April/May 2005

Read More Show Less

Product Details

Meet the Author

Hugo Kubinyi studied chemistry in Vienna, Austria. After his Ph.D. thesis at the Max Planck Institute of Biochemistry in Munich he continued as a PostDoc at the German Cancer Research Centre in Heidelberg. In 1966 he joined Knoll AG, later a subsidiary of BASF AG, and in 1985 he moved to BASF AG. Since 1987, until his retirement in summer 2001, he was responsible for the Molecular Modelling, Protein Crystallography and Drug Design group of BASF, since early 1998 also for Combinatorial Chemistry in the Life Sciences.
He is Professor of Pharmaceutical Chemistry at the University of Heidelberg, former Chair of The QSAR and Modelling Society, and IUPAC Fellow. From his scientific work resulted five books on QSAR, 3D QSAR, and Drug
Design (the German book "Wirkstoffdesign" received the 1999 Book Award of the FCI, Association of Chemical Industry) and about 90 publications.
He is a member of several Scientific Advisory Boards, coeditor of the Wiley-VCH book series "Methods and Principles in Medicinal Chemistry", and member of the Editorial Boards of several scientific journals.

Gerhard M?ller graduated in Organic Chemistry from the University of Frankfurt/Main (Germany) and received his PhD in 1992 at the Technical University of Munich. After two years in the Medicinal Chemistry department of Glaxo Verona (Italy), he joined the central research facility of the Bayer AG, Leverkusen. From 1998 onwards he was project manager of a target family approach in medicinal chemistry. From 2001 to 2003 he headed the chemistry section of Organon's Lead Discovery Unit in Oss (The Netherlands). Since summer 2003, Gerhard M?ller is the chief scientific officer of the Munich-based biotech company Axxima Pharmaceuticals AG.

Read More Show Less

Table of Contents

Introduction
GENERAL ASPECTS
Target Family-directed Masterkeys
Drug Discovery from Side Effects
Chemical Genetics in Drug Discovery
Structural Aspects of Binding Site Similarity
TARGET FAMILIES
Knowledge-based Discovery of Biological Targets
Chemical Kinomics
Kinase Inhibitors
Ion Channel Modulators
Phosphodiesterase Inhibitors
Proteochemometrics
CHEMICAL LIBRARIES
Compound Library and Template Design for GPCRs
Computational Filters in Lead Generation
Ligand-based Design of Focused Libraries
Natural Product-derived Combinatorial Libraries
Combinatorial Chemistry in the Chemical Genomics Age
Read More Show Less

Customer Reviews

Be the first to write a review
( 0 )
Rating Distribution

5 Star

(0)

4 Star

(0)

3 Star

(0)

2 Star

(0)

1 Star

(0)

Your Rating:

Your Name: Create a Pen Name or

Barnes & Noble.com Review Rules

Our reader reviews allow you to share your comments on titles you liked, or didn't, with others. By submitting an online review, you are representing to Barnes & Noble.com that all information contained in your review is original and accurate in all respects, and that the submission of such content by you and the posting of such content by Barnes & Noble.com does not and will not violate the rights of any third party. Please follow the rules below to help ensure that your review can be posted.

Reviews by Our Customers Under the Age of 13

We highly value and respect everyone's opinion concerning the titles we offer. However, we cannot allow persons under the age of 13 to have accounts at BN.com or to post customer reviews. Please see our Terms of Use for more details.

What to exclude from your review:

Please do not write about reviews, commentary, or information posted on the product page. If you see any errors in the information on the product page, please send us an email.

Reviews should not contain any of the following:

  • - HTML tags, profanity, obscenities, vulgarities, or comments that defame anyone
  • - Time-sensitive information such as tour dates, signings, lectures, etc.
  • - Single-word reviews. Other people will read your review to discover why you liked or didn't like the title. Be descriptive.
  • - Comments focusing on the author or that may ruin the ending for others
  • - Phone numbers, addresses, URLs
  • - Pricing and availability information or alternative ordering information
  • - Advertisements or commercial solicitation

Reminder:

  • - By submitting a review, you grant to Barnes & Noble.com and its sublicensees the royalty-free, perpetual, irrevocable right and license to use the review in accordance with the Barnes & Noble.com Terms of Use.
  • - Barnes & Noble.com reserves the right not to post any review -- particularly those that do not follow the terms and conditions of these Rules. Barnes & Noble.com also reserves the right to remove any review at any time without notice.
  • - See Terms of Use for other conditions and disclaimers.
Search for Products You'd Like to Recommend

Recommend other products that relate to your review. Just search for them below and share!

Create a Pen Name

Your Pen Name is your unique identity on BN.com. It will appear on the reviews you write and other website activities. Your Pen Name cannot be edited, changed or deleted once submitted.

 
Your Pen Name can be any combination of alphanumeric characters (plus - and _), and must be at least two characters long.

Continue Anonymously

    If you find inappropriate content, please report it to Barnes & Noble
    Why is this product inappropriate?
    Comments (optional)